Contributors: Center for Genetic Engineering and Biotechnology Cuba (CIGB); Ehime University Matsuyama, Japon; Bangabandhu Sheikh Mujib Medical University Dakha, Bangladesh (BSMMU, IPGMR); Oita University Faculty of Medicine Oita, Japon; Helmholtz Centre for Infection Research (HZI); Hospital Abel Santamaria, Pinar del Rio, Cuba; Partenaires INRAE; Pathogenèse des Virus de l'Hépatite B (PVHB); Institut Pasteur Paris (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM); Laboratoire commun Pasteur-TheraVectys; Institut Pasteur Paris (IP)-TheraVectys-Université Paris Cité (UPCité); National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba; Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB); Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Infectious Diseases Models for Innovative Therapies (IDMIT); Université Paris-Saclay-Institut de Biologie François JACOB (JACOB); Direction de Recherche Fondamentale (CEA) (DRF (CEA)); Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)); Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
نبذة مختصرة : International audience ; The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low-and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.
Processing Request
No Comments.